Picture of Crinetics Pharmaceuticals logo

CRNX — Crinetics Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Crinetics Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

* Crinetics Pharmaceuticals Inc  CRNX.OQ  reported a
quarterly
adjusted loss of 96 cents​​ per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of $-1.01.  The mean expectation of
thirteen analysts for the quarter was for a loss of 91 cents per
share. Wall Street expected results to range from $-1.03 to -74
cents per share.
    * Reported revenue was zero​; analysts expected $240.00
thousand. 
    * Crinetics Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 96 cents​.
    * The company reported a quarterly loss of $76.83 million.
    * Crinetics Pharmaceuticals Inc shares had risen by 15.0%
this
quarter and gained 65.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Crinetics
Pharmaceuticals Inc is 70.00 
This summary was machine generated from LSEG data November 13 at
02:26 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.91          -0.96          Missed
 Jun. 30 2024      -0.86          -0.94          Missed
 Mar. 31 2024      -0.81          -0.93          Missed
 Dec. 31 2023      -0.86          -0.90          Missed

Recent news on Crinetics Pharmaceuticals

See all news